Drug delivery to the CNS and polymeric nanoparticulate carriers

Future Medicinal Chemistry

Volumn 2, Issue 11, 2010, Pages 1681-1701

  Costantino, Luca ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALBUMIN TC 99M; AMINOLEVULINIC ACID; ANG 1005; ANGIOPEP 2; DENDRIMER; DIPHTHERIA TOXOID CRM197; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; GLUTATHIONE; INSULIN RECEPTOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LEVODOPA; LIPOSOME; LOPERAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NANOPARTICLE; NIPECOTIC ACID; PACLITAXEL; PENETRATIN; PEPTIDE; POLYAMIDOAMINE; POLYGLACTIN; POLYSORBATE 80; RITONAVIR; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD BRAIN BARRIER; CATIONIZATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RELEASE; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; HUMAN; IMMUNOGENICITY; IONIZATION; LIVER CELL CARCINOMA; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR STRUCTURE; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; POLYMERS;

EID: 78649231509     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.249     Document Type: Review

References (172)

1. Calabria AR, Shusta EV. Blood-brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery. Drug Discov. Today 11, 792-799 (2006).
2. Pardridge WM. Blood-brain barrier delivery. Drug Discov. Today 12, 54-61 (2007).
3. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298, 274-292 (2005).
4. Lampson LA. Targeted therapy for neuro-oncology: reviewing the menu. Drug Discov. Today 14, 185-191 (2009).
5. Stenehjem DD, Hartz AMS, Bauer B, Anderson GW. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Fut. Med. Chem. 1, 1623-1641 (2009).
6. Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J. Med. Chem. 49, 7559-7583 (2006).
7. Prokai-Tatrai K, Prokai L. Modifying peptide properties by prodrug design for enhanced transport into the CNS. In: Peptide Transport and Delivery Into the Central Nervous System. Prokai-Tatrai K, Prokai L (Eds.). Birkhauser-Verlag, Basel, Switzerland, 155-188 (2003).
8. Kerns EH, Di L. Chapter 10. In: Drug-like Properties: Concepts, Structure Design and Methods. Academic Press 122-136 (2008).
9. Reichel A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chem. Biodiversity 6, 2030-2049 (2009).
10. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm. Res. 25, 1737-1750 (2008).
11. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor mediation. Pharm. Res. 24, 1759-1771 (2007).
12. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifcations of drugs or drug-nanoparticles? Drug Discov. Today 13, 1099-1106 (2008).
13. Kumagai AK, Eisenberg WM, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a b-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J. Biol. Chem. 262, 15214-15219 (1987).
14. Trigueiro D, Buciak JB, Pardridge WM. Capillary depletion method for quantifying blood-brain barrier transcytosis of circulating peptides and plasma proteins. J. Neurochem. 54, 1882-1888 (1990).
15. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Del. Rev. 46, 247-279 (2001).
16. Lee HJ, Pardridge WM. Pharmacokinetics and delivery of Tat and Tat-protein conjugates to tissues in vivo. Bioconj. Chem. 12, 995-999 (2001).
17. Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Del. Rev. 57, 529-545 (2005).
18. DeBoer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain barrier. Clin. Pharmacokinet. 46, 553-576 (2007).
19. Rousselle C. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol. Pharmacol. 57, 679-686 (2000).
20. Rousselle C, Clair P, Smirnova M et al. Improved brain uptake and pharmacological activity of dalargin using a peptide vector mediated strategy. J. Pharmacol. Exp. Ther. 306, 371-376 (2003).
21. Malakoutikhah M, Teixido M, Giralt E. Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries. J. Med. Chem. 51, 4881-4889 (2008).
22. Malakoutikhah M, Prades R, Teixido M, Giralt E. N-methyl phenylalanine-rich peptides as highly versatile blood-brain barrier shuttles. J. Med. Chem. 2354-2363 (2010).
23. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Disease 37, 48-57 (2010).
24. Van Rooy I, Cakir-Tascioglu S, Couraud PO et al. Identifcation of peptide ligands for targeting to the blood-brain barrier. Pharm. Res. 27, 673-682 (2010).
25. Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-a-tocopheryl. polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 31(30), 7748-7757 (2010).
26. Kumar P, Wu HQ, Jodi LM et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43 (2007).
27. Pan W, Kastin AJ, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Effcient transfer of receptor-associated protein (RAP) across the blood-brain barrier J. Cell Sci. 117, 5071-5078 (2004).
28. Prince WS, Cormick LM, Wendt DJ et al. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusion between the receptor-associated protein (RAP) and a-iduronidase or acid a-glucosidase. J. Biol. Chem. 279, 35037-35046 (2004).
29. Demeule M, Regina A, Che C et al. Identifcation and design of peptides as new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324, 1064-1072 (2008).
30. Thomas FC, Taskar K, Rudraraju V et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26, 2486-2494 (2009).
31. Regina A, Demeule M, Che C et al. Anti-tumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155, 185-197 (2008).
32. Drappatz J, Brenner A, Rosenfeld S et al. Ang-1005: new EPiC compound for the treatment of recurrent malignant glioma. Presentated at: The EORTC-NCI-AACR Annual Meeting 2009, Boston, MA, USA, 15-19 November, 2009.
33. Che C, Yang G, Thiot C et al. New angiopep-modifed doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53, 2814-2824 (2010).
34. Esfand R, Tomalia DA. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6,427-436 (2001).
35. Medina SH, El-Sayed EH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev. 109, 3141-3157 (2009).
36. Astruc D, Boisselier E, Ornelas C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem. Rev. 110, 1857-1959 (2010).
37. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur. J. Pharm. Sci. 38, 185-196 (2009).
38. Zhang L, Gu F, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008).
39. Ke W, Shao K, Huang R et al. Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modifed polyamidoamine dendrimers. Biomaterials 30, 6976-6985 (2009).
40. Huang RQ, Ke WL, Liu Y, Chen J, Pei YY. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29, 238-246 (2008).
41. Liu Y, Huang R, Han L et al. Brain-targeting gene delivery and cellular internalization mechanisms for modifed rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195-4202 (2009).
42. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery ACS Nano 3, 16-20 (2009).
43. Huang G, Zhang N, Bi X, Dou M. Solid lipid nanoparticles of temozolomide: potential reduction of cardiac and nephric toxicity. Int. J. Pharm. 355, 314-320 (2008).
44. Kaur IP, Bhandari R, Bhandari S, Kakkar V, Potential of solid-lipid nanoparticles in brain targeting. J. Contr. Rel. 127, 97-109 (2007).
45. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71, 161-172 (2009).
46. Costantino L, Tosi G, Ruozi B, Bondioli L, Vandelli MA, Forni F. Colloidal systems for CNS drug delivery. Progr. Brain Res. 180, 35-69 (2009).
47. Saad M, Garbuzenko OB, Ber E et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most effcient for tumor-specifc treatment and imaging? J. Contr. Rel. 130, 107-114 (2008).
48. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Exp. Opin. Drug Del. 5, 155-174 (2008).
49. Owens DE, Peppas NA. Opsonization, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006).
50. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonisation and protein-binding properties. Prog. Lipid Res. 42, 463-478 (2003).
51. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic effcacy. Adv. Drug Del. Rev. 61, 428-437 (2009).
52. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil S. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects of nanoparticle biodistribution. Mol. Pharmaceutics 5, 487-495 (2008).
53. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Del. Rev. 47, 65-81 (2001).
54. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceutics 5, 505-515 (2008).
55. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharmaceutics 5, 496-504 (2008).
56. Cho WS, Cho M, Jeong J et al. Size-dependent kinetics of PEG-coated gold nanoparticles. Toxicol. App. Pharmacol. 245, 116-123 (2010).
57. He C, Hu Y, Tang C, Yin C. Effect of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657-3666 (2010).
58. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 69, 1-9 (2008).
59. Zhang L, Chan JM, Gu FX et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2, 1696-1702 (2008).
60. 14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J. Drug Targ. 14, 97-105 (2006).
61. Besheer A, Vogel J, Glanz D, Kressler J, Groth T, Mader K. Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modifed hydroxyethyl starch vs Pluronics. Mo l. Pharmaceutics 6, 407-415 (2009).
62. Sahagun G, Moore SA, Hart MN. Permeability of neutral vs anionic dextrans in cultured brain microvascular endothelium. Am. J. Physiol. 259, H162-H166 (1990).
63. Gaumet M, Gurny R, Delie F. Localization and quantifcation of biodegradable particles in an intestinal cell model: the infuence of particle size. Eur. J. Pharm. Sci. 36, 465-473 (2009).
64. Gao K, Jiang X, Infuence of particle size on transport of methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 310, 213-219 (2006).
65. Xu P, Gullotti E, Tong L et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol. Pharmaceutics 6, 190-201 (2009).
66. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat. Mater. 8, 15-23 (2009).
67. Doshi N, Mitragotri S. Designer biomaterials for nanomedicine. Adv. Funct. Mater. 19, 3843-3854 (2009).
68. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103, 4930-4934 (2006).
69. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of Docetaxel-loaded hydrophobically modifed glycol chitosan nanoparticles. J. Contr. Rel. 128, 23-31 (2008).
70. Sun X, Rossin R, Turner JL et al. An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules 6, 2541-2554 (2005).
71. Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: infuences of surface morphology, length, and type of polysaccharide. Pharm. Res. 23, 1313-1323 (2006).
72. Costantino L, Gandolf F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Contr. Rel. 108, 84-96 (2005).
73. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Contr. Rel. 107, 428-448 (2005).
74. Hu K, Li J, Shen Y et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Contr. Rel. 134, 55-61 (2009).
75. Zhang Z, Feng SS. In vitro investigation of poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialisys method for chemotherapy. Biomacromolecules 7, 1139-1146 (2006).
76. Huang CY, Lee YD. Core-shell type of nanoparticles composed of poly[(n-butyl cyanoacrylate)-co-(2-octyl cyanoacrylate)] copolymers for drug delivery application: synthesis, characterization and in vivo degradation. Int. J. Pharm. 325, 132-139 (2006).
77. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Del. Rev. 55, 519-548 (2003).
78. Yoon SJ, Kim SH, Ha HJ et al. Reduction of infammatory reaction of poly(D,L-lactic-co-glycolic acid) using demineralised bone particles. Tissue Eng. Part A, 14, 539-547 (2008).
79. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Del. Rev. 28, 5-24 (1997).
80. Lherm C, Muller RH, Puisieux F, Couvreur P. Alkylcyanoacrylate drug carriers II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int. J. Pharm. 84, 13-22 (1992).
81. Maurer-Jones MA, Bantz KC, Love SA, Marquis BJ, Haynes CL. Toxicity of therapeutic nanoparticles. Nanomedicine 4, 219-241 (2009).
82. Xia T, Kovochich M, Liong M, Zink JI, Nel AE. Cationic polystyrene nanosphere toxicity depends on cell-specifc endocytic and mitochondrial injury pathways. ACS Nano 2, 85-96 (2008).
83. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29, 4429-4438 (2008).
84. Jiskoot W, van Schie RMF, Carstens MG, Schellekens H. Immunological risk of injectable drug delivery systems. Pharm. Res. 26, 1303-1314 (2009).
85. Bertholon I, Vauthier C, Labarre C. Complement activation by core-shell poly(isobutylcyanoacrylate)-olysaccharide nanoparticles: infuences of surface morphology, length, and type of polysaccharide. Pharm. Res. 23, 1313-1323 (2006).
86. Hamada I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol) generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunol. 46, 225-232 (2008).
87. Lu W, Wan J, She Z, Jiang X, Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Contr. Rel. 118, 38-53 (2007).
88. Simeonova M, Chorbadjiev K, Antcheva M. Study of the effect of polybutylcyanoacrylate nanoparticles and their metabolites on the primary immune response in mice to sheep red blood cells. Biomaterials 19, 2187-2193 (1998).
89. Arima Y, Kawagoe M, Toda M, Iwata H. Complement activation by polymers carrying dhydroxyl groups. A CS Appl. Mat. Interfaces 1, 2400-2407 (2009).
90. Koziara JM, Oh JJ, Akers WS, Ferraris SP, Mumper RJ. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22, 1821-1828 (2005).
91. Kim D, El-Shall H, Dennis D, Morey T. Interaction of PLGA nanoparticles with human blood constituents. Colloids and Surf. B Biointerfaces 40, 83-91 (2005).
92. Rajendran L, Knolker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. Nature Rev. Drug Disc. 9, 29-42 (2010).
93. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(D,L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16, 1217-1226 (2002).
94. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J. Drug Target. 12, 635-641 (2004).
95. Brigger I, Morizet J, Laudani L et al. Negative preclinical results with stealth nasnospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Contr. Rel. 100, 29-40 (2004).
96. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105, 14265-14270 (2008).
97. Langer K, Seegmuller E, Zimmer A, Kreuter J. Characterization of polybutylcyanoacrylate nanoparticles: I. Quatifcation of PBCA polymer and dextrans. Int. J. Pharm. 110, 21-27 (1994).
98. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifers. J. Contr. Rel. 130, 98-106 (2008).
99. Huang JG, Si LQ, Jiang LL, Fan ZZ, Qiu J, Li G. Effect of Pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. Int. J. Pharm. 351-353 (2008
100. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Contr. Rel. 82, 105-114 (2002).
101. Sun W, Xie C, Wang H, Hu Y. Specifc role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 25, 3065-3071 (2004).
102. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur J. Pharm. Biopharm. 68, 112-128 (2008).
103. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J. Contr. Rel. 145, 182-195 (2010).
104. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int. J. Pharm. 244, 105-115 (2002).
105. Zauner W, Farrow NA, Haines AM. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density J. Contr. Rel. 71, 39-51 (2001).
106. Torchilin VP. Rrecent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng 8, 343-375 (2006).
107. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular traffcking in nonviral gene delivery. Pharmacol. Rev. 58, 32-45 (2006).
108. Tahara K, Yamamoto H, Kawashima Y Cellular uptake mechanism and intracellular distribution of polysorbate 80-modifed poly(D,L-lactide-co- glycolide) nanospheres for gene delivery. Eur. J. Pharm. Biopharm. 75, 218-224 (2010).
109. Calvo P, Gouritin B, Chacun H et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18, 1157-1166 (2001). (Pubitemid 32900402)
110. Kim HR, Gil S, Andrieux K et al. Low density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell. Mol. Life Sci. 64, 356-364 (2007). (Pubitemid 46440206)
111. Garcia-Garcia E, Andrieux K, Gil S et al. A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int. J. Pharm. 298, 310-314 (2005).
112. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J. Contr. Rel. 93, 271-282 (2003).
113. Koziara J, Lockman PR, Allen DD, Mumper RJ, In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20, 1772-1778 (2003).
114. Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen DD. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20, 705-713 (2003).
115. Menei P, Daniel V, Montero-Menei C, Brouillard M, Pouplard-Barthelaix A, Benoit JP. Biodegradation and brain tissue reaction of poly(D,L-lactide-co- glycolide) microspheres. Biomaterials 14, 470-478 (1993).
116. Nicholas AP, McInnis C, Gupta KB et al. The fate of biodegradable microspheres injected into rat brain. Neurosci. Lett. 323, 85-88 (2002).
117. Chernenko T, Matthaus C, Milane L, Quintero L, Amiji M, Diem M. Label-free raman spectral imaging of intracellular delivery and degradation of polymeric nanoparticle system. ACS Nano 3, 3552-3558 (2009).
118. Van Apeldoorn A, van Manen H, Bezemer J, de Bruijn, J, van Blitterswijk C, Otto C. Raman imaging of PLGA microspheres degradation inside macrophages. J. Am. Chem. Soc. 126, 13226-13227 (2004).
119. 14C] poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13, 1093-1102 (1992).
120. Muller RH, Lherm C, Herbert J, Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 11, 590-595 (1990).
121. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanoparticles. J. Biol. Chem. 284, 6972-6981 (2009).
122. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Contr. Rel. 137, 78-86 (2009).
123. Cartiera M, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30, 2790-2798 (2009).
124. Hu YL, Gao JQ. Potential neurotoxicity of nanoparticles. Int. J. Pharm. 394, 115-121 (2010).
125. Reis SA, Willemsen R, van Unen L, Hoogeveen AT, Oostra BA. Prospect of TAT-mediated protein therapy for fragile X syndrome. J. Mol. Histol. 35, 389-395 (2004).
126. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119 (2005).
127. Sharma HS. Nanoneuroscience: emerging concepts on nanoneurotoxicity and nanoneuroprotection. Nanomedicine 2, 753-758 (2007).
128. 14C in the rat. Am. J. Physiol. 221, 214-217 (1971).
129. Alyautdin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butyl cyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Targ. 19, 209-221 (2001).
130. Thole M, Nobmann S, Huwyler J, Bartmann A, Fricker G. Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J. Drug Targ. 10, 337-344 (2002).
131. Parikh T, Bommana MM, Squillante E. Effcacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur. J. Pharm. Biopharm. 74, 442-450 (2010).
132. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles fort the delivery of drugs to the brain. Biomaterials 31, 908-915 (2010).
133. Kreuter J. Infuence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotech. 4, 484-488 (2004).
134. Garcia-Garcia E, Gil S, Andrieux K et al. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. CMLS Cell. Mol. Life Sci. 62, 1400-1408 (2005).
135. Hekmatara T, Gelperina S, Vitali V, Yang, SR, Kreuter J. Encapsulation of water-insoluble drugs in poly(butyl cyanoacrylate) nanoparticles J. Nanosci. Nanotech. 9, 5091-5098 (2009).
136. Reimold I, Domke D, Bender J, Seyfried CA, Radunz HE, Fricker G. Delivery of nanoparticles to the brain detected by fuorescence microscopy. Eur. J. Pharm. Biopharm. 70, 627-632 (2008).
137. Weiss CK, Kohnle M V, Landfester K et al. The frst step into the brain: uptake of NIO PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. ChemMedChem. 3, 1395-1403 (2008).
138. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16, 1836-1842 (1999).
139. Kreuter J, Ramge P, Petrov V et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specifc mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20, 409-416 (2003).
140. Azmin MN, Stuart JFB, Florence AT. The distribution and elimination of metotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother. Pharmacol. 14, 238-242 (1985).
141. Sakane T, Tanaka C, Yamamoto A et al. The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyothorphin. Int. J. Pharm. 57, 77-83 (1989).
142. Schroeder U, Schroeder H, Sabel BA. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci. 66, 495-502 (2000
143. Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE et al. Brain targeting of Nerve Growth Factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Targ. 17, 564-574 (2009).
144. Michaelis K, Hoffmann MM, Dreis S et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317, 1246-1253 (2006 ).
145. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K, Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J. Contr. Rel. 118, 54-58 (2007).
146. Lemarchand C, Gref R, Passirani C et al. Infuence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials 27, 108-118 (2006).
147. Goppert TM, Muller RH. Plasma protein adsorption on Tween 80 and Poloxamer 188-stabilized solid lipid nanoparticles. J. Drug Targ. 11, 225-231 (2003).
148. Kreuter J. Use of nanoparticles for cerebral cancer. Tumor. 94, 271-277 (2008).
149. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: infuence of the formulation parameters. Eur. J. Pharm. Biopharm. 74, 157-163 (2010).
150. Petri B, Bootz A., Khalansky A et al. Chemotherapy of brain tumor using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Contr. Rel. 117, 51-58 (2007).
151. Sun W, Wang H, Xie C, Hu Y, Yang X, Xu H. An attempt to directly trace polymeric nanoparticles in vivo with electron microscopy. J. Contr. Rel. 115, 259-265 (2006). (Pubitemid 44634845)
152. Santander-Ortega MJ, Jodar-Reyes AB, Csaba N, Bastos-Gonzalez D, Ortega-Vinuesa JL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms. J. Colloid Interface Sci. 302, 522-529 (2006).
153. Kim HR, Andrieux K, Gil S et al. Translocation of poly (ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8, 793-799 (2007).
154. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth Doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Targ. 10, 327-335 (2002).
155. Ulbrich K, Hekmatara E, Kreuter J. Transferrin- and transferrin-receptor- antibody-modifed nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71, 251-256 (2009).
156. Aktas Y, Yemisci M, Andrieux K.et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconj. Chem. 16, 1503-1511 (2005).
157. Karatas H, Aktas Y, Gursoy-Ozdemir Y et al. A nanomedicine transports a peptide Caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci. 29, 13761-13769 (2009).
158. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Berolini A, Costantino L. Nanoparticles as drug delivery agents specifc for CNS: in vivo biodistribution. Nanomedicine: NBM 5, 369-377 (2009).
159. Brigger I, Morizet J, Aubert G et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J. Pharmacol. Exp. Ther. 303, 928-936 (2002).
160. 14C]poly(D, L-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int. J. Pharm. 106, 201-211 (1994).
161. 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models. Pharm. Res. 18, 1613-1619 (2001).
162. Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654-1673 (2010).
163. Veldhorst-Janssen NML, Fiddelers AAA, van der Ruy PHM, Neef C, Marcus MAE. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin. Ther. 31, 2954-2987 (2009).
164. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose to brain delivery of drugs. Int. J. Pharm. 379, 146-157 (2009).
165. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 14, 3754-3779 (2009).
166. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J. Pharm. Sci. 96, 473-483 (2007).
167. Schroeder U, Sommerfeld P, Sabel BA, Effcacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 19, 777-780 (1998). (Pubitemid 28255016)
168. Das D, Lin SS. Double-coated poly(butylcyanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 94, 1343-1353 (2005).
169. Putney SD, Burke PA. Improving protein therapeutics with sustained-release formulations. Nat. Biotech. 16, 153-157 (1998).
170. He W, Jiang X, Zhang ZR. Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin. J. Pharm. Sci. 97, 2250-2259 (2008).
171. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17, 1159-1167 (2000).
172. Yang SX, Yuan WE, Jin T. Formulating protein therapeutics into particulate forms. Exp. Opin. Drug Del. 6, 1123-1133 (2009).